Quick Answer
Aclaris Therapeutics, Inc. reported Operating Income Loss of -$76.38 million for the year ending 2025.
- Aclaris Therapeutics, Inc. showed an increase of +46.2% in Operating Income Loss from 2024 to 2025.
- This data is from Aclaris Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 13 years of available data (2013 to 2025), Aclaris Therapeutics, Inc.'s Operating Income Loss has declined by 1,352.8%.
- Historical annual values: Fiscal year 2025: -$76.38 million | Fiscal year 2024: -$141.93 million | Fiscal year 2023: -$97.36 million | Fiscal year 2022: -$89.85 million | Fiscal year 2021: -$89.72 million | Fiscal year 2020: -$50.91 million | Fiscal year 2019: -$111.06 million | Fiscal year 2018: -$84.78 million | Fiscal year 2017: -$54.36 million | Fiscal year 2016: -$48.57 million | Fiscal year 2015: -$20.67 million | Fiscal year 2014: -$8.53 million | Fiscal year 2013: -$5.26 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: